Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 studynews2025-09-10T13:39:50+00:00September 10th, 2025|Endpoints News|
New FDA approval pathway for n-of-1 therapies coming soon, Prasad saysnews2025-09-08T18:57:01+00:00September 8th, 2025|Endpoints News|
China biotech Epigenic raises $60M to test CRISPR epigenetic therapiesnews2025-09-08T02:00:04+00:00September 8th, 2025|Endpoints News|
Regenxbio trumpets one-year data for Hunter syndrome gene therapy after FDA extended its reviewnews2025-09-05T14:14:19+00:00September 5th, 2025|Endpoints News|
CDER and CBER offer new submission program for rare disease gene therapiesnews2025-09-03T15:41:24+00:00September 3rd, 2025|Endpoints News|
Exclusive: Mytos inks cell therapy manufacturing deals with three European biotechs news2025-09-03T07:00:17+00:00September 3rd, 2025|Endpoints News|
Vertex enlists Enlaza for gene therapy conditioning and autoimmune disease pactnews2025-09-02T15:34:54+00:00September 2nd, 2025|Endpoints News|
Wugen collects $115M as it runs pivotal allogeneic CAR-T trialnews2025-08-27T11:00:58+00:00August 27th, 2025|Endpoints News|
FDA lifts hold on Rocket’s pivotal study for its gene therapy, which is now a lower dosenews2025-08-20T14:59:39+00:00August 20th, 2025|Endpoints News|
Catalent lays off 350 workers over change in demand from a ‘large customer’ news2025-08-20T11:20:59+00:00August 20th, 2025|Endpoints News|
